In addition to models of PD, β2AR agonists have been reported to be neuroprotective in preclinical models of ischemic stroke76 and excitotoxicity70, promote neurogenesis, dendritic branching and decrease cerebral amyloid plaques in the APP/PS1 transgenic mouse Alzheimer model, and produce motor benefits in the SOD1G93A transgenic ALS mouse model77. This evidence concerns the gene APP and Parkinson disease.